Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology (NASDAQ: POAI) has achieved significant milestones in its ovarian cancer research, completing genomic and transcriptomic sequencing in collaboration with UPMC-Magee Women Hospital. This data will form the backbone of AI-driven predictive models for patient outcomes and aid in an internal drug repurposing initiative. CEO Dr. Schwartz emphasized the potential of leveraging unique assets to create value and expand AI-driven clinical models across various cancers.
Predictive Oncology (NASDAQ: POAI) has successfully completed a private placement of common stock and warrants, raising $17.6 million. The company issued 9,043,766 shares at $1.95 per share and warrants for an additional 4,521,883 shares at an exercise price of $2.00. Proceeds will be allocated to debt repayment and corporate purposes. The company is required to file a registration statement covering the resale of these shares within five days, aiming for effectiveness within 90 days.
On February 18, 2021, Predictive Oncology Inc. (NASDAQ: POAI) announced a private placement to raise approximately $17.6 million by issuing 9,043,766 shares of its common stock and warrants for 4,521,883 shares at $1.95 per share. The placement is expected to close around February 22, 2021, pending customary conditions. The company plans to utilize approximately $5.88 million of the proceeds to repay debt and the remainder for corporate purposes. The warrants have an exercise price of $2.00 and a term of five and a half years.
Predictive Oncology (NASDAQ: POAI) announced significant advancements in ovarian cancer research through its subsidiary, TumorGenesis. Researchers utilized TumorGenesis’s media to study how ovarian cancer cells migrate, which could lead to targeted drug therapies aimed at blocking metastasis. This research highlights the potential for several billion dollars in future revenues for biotech companies. Additionally, the study identified a mechanism involving PARP inhibitors, which, when combined with PARGs, could improve patient outcomes. This research underscores the role of AI in personalized medicine and drug discovery.
Predictive Oncology (NASDAQ: POAI) announced the closing of a registered direct offering of 4,222,288 common shares at $1.75 per share, generating approximately $7.4 million in gross proceeds. The offering was conducted under Nasdaq regulations and included unregistered warrants for 2,111,144 shares at an exercise price of $2.00. The company plans to use the net proceeds for working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
Predictive Oncology Inc. (NASDAQ: POAI) has announced a registered direct offering, issuing approximately 4.22 million shares at $1.75 per share, resulting in gross proceeds of about $7.4 million. The company will also issue warrants for up to 2.11 million shares with an exercise price of $2.00 per share. The offering is set to close on or around February 16, 2021. Funds will be directed towards working capital. The shares are offered under a previously filed registration statement with the SEC.
Predictive Oncology (NASDAQ: POAI) announced the initiation of an in-house drug repurposing project targeting ovarian cancer using its AI-driven platform, PeDAL™. This project aims to quickly and affordably profile existing drugs across various patient cell lines, generating vital data to enhance the PeDAL approach and enrich the company's Intellectual Property. CEO Dr. Carl Schwartz emphasized the project’s potential to add significant value through proof data, supporting commercial negotiations with pharmaceutical firms and positioning the company as a leader in AI-driven drug discovery.
Predictive Oncology (NASDAQ: POAI) announced a new contract with a large pharmaceutical company through its subsidiary Soluble Biotech. This collaboration aims to enhance the solubility and stability of a protein therapeutic for future clinical use. Dr. Larry DeLucas, President of Soluble Biotech, indicated this opportunity could pave the way for a long-term strategic partnership, supporting additional therapeutics under development by the pharmaceutical company. Predictive Oncology utilizes AI in personalized medicine and operates across several segments.
Predictive Oncology (NASDAQ: POAI) announced the closing of a registered direct offering of 3,414,970 shares at $1.20 each, generating approximately $4.1 million in gross proceeds. Concurrently, the company issued unregistered warrants for 1,707,485 additional shares at an exercise price of $1.37. The funds from this offering will be used for working capital. H.C. Wainwright & Co. acted as the exclusive placement agent. The warrants and underlying shares have not been registered and may not be sold in the U.S. without an effective registration statement.
Predictive Oncology (NASDAQ: POAI) announced a registered direct offering of approximately 3,414,970 shares of common stock at $1.20 per share, generating approximately $4.1 million in gross proceeds. The offering includes unregistered warrants for up to 1,707,485 additional shares at an exercise price of $1.37, expiring in five and a half years. The funds will be used for working capital, with the offering's closing expected around January 26, 2021. The transaction is facilitated by H.C. Wainwright & Co.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
